SynthesisCancer medicine2025
Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis.Cancer medicine · 2025Pooled it
- FLT3-mutated AML: standards of care and ongoing investigation.Blood research · 2026Review
- Hematological Malignancies: Molecular Mechanisms and Therapy, Second Edition.International journal of molecular sciences · 2026Article
- Controversies in the Management of AML in Older Patients: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2026Review
- Predicting the Regulatory Dynamics of AML Disease Progression from Longitudinal Multi-Modal Clinical Data.Journal of medical systems · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFms-like tyrosine kinase 3 (FLT3) mutations are associated with poor prognosis in patients with acute myeloid leukaemia (AML).
aimsWe conducted a systematic literature review and meta-analyses of studies reporting FLT3 mutation prevalence in patients with AML. MATERIALS &
methodsWe searched all publications through September 2022; the earliest publication we retrieved was published in 1997. Based on these publications, data from the studies were generated between 1985 and 2021. Prevalence was evaluated overall and by study type, geographic location of study, patient age, and gender.
resultsWeighted mean (95% confidence interval) prevalence for FLT3 internal tandem duplication (ITD) and FLT3 tyrosine kinase domain (TKD) mutations were 20% (19%-22%) and 7% (6%-8%), respectively, with wide variability in individual study estimates (FLT3-ITD: 5.1%-41.4%; FLT3-TKD: 2.3%-12.0%). Weighted mean prevalence estimates for FLT3-ITD and FLT3-TKD mutations were higher in populations from interventional (FLT3-ITD: 22%; FLT3-TKD: 8%) than non-interventional studies (FLT3-ITD: 19%; FLT3-TKD: 6%). Weighted mean FLT3 mutation prevalence estimates were higher for Europe (FLT3-ITD: 23%; FLT3-TKD: 8%) and lower for Asia (FLT3-ITD: 18%; FLT3-TKD: 5%). Weighted mean prevalence of FLT3-ITD mutations was higher in younger adults (aged 18-59 years; 23%) than paediatric (aged < 18 years; 12%) or older (aged ≥ 60 years; 18%) populations, and in females (22%) than males (18%). DISCUSSION: This was the first study to comprehensively assess the reported prevalence of FLT3 mutations worldwide among AML patients.
conclusionWe described the distribution of FLT3 mutations; further work is needed to understand prevalence estimate heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.